Anidulafungin

Anidulafungin

Min.Order / FOB Price:Get Latest Price

1 Kilogram

Negotiable

Min.Order :1 Kilogram
Purity: USP/EP/BP
Payment Terms : L/C,T/T,Other

Keywords

166663-25-8 Ecalta Eraxis

Quick Details

Appearance:White crystallization
Application:oral anticoagulant drug
PackAge:25kg/drum
ProductionCapacity:10|Metric Ton|Day
Storage:room temperature
Transportation:AIR SEA TRAIN

Superiority:

Product Name:	Anidulafungin
Synonyms:	Anidulafungin;Echinocandin B, 1-(4R,5R)-4,5-dihydroxy-N2-4-(pentyloxy)1,1:4,1-terphenyl-4-ylcarbonyl-L-ornithine-;Anidulafungin(LY303366);Ecalta;Eraxis;LY 303366;LY 303366, Eraxis;1-[(4R,5R)-4,5-dihydroxy-N2-[[4''-(pentyloxy)[1,1'',1''-terphenyl]-4-yl]carbonyl]-L-ornithine]-echinocandin B
CAS:	166663-25-8
MF:	C58H73N7O17
MW:	1140.24
EINECS:	658-060-4
Product Categories:	Inhibitors;Antifungals;API
Mol File:	166663-25-8.mol

Anidulafungin Chemical Properties

Melting point	>196°C (subl.)
Boiling point	1477.0±65.0 °C(Predicted)
density	1.47±0.1 g/cm3(Predicted)
storage temp.	under inert gas (nitrogen or Argon) at 2-8°C
solubility	DMSO (Slightly, Heated), Methanol (Slightly)
pka	9.86±0.26(Predicted)
form	Solid
color	White to Pale Beige

Details:

Description	Anidulafungin, a semi-synthetic derivative of echinocandin B, has been developed and launched as an intravenous treatment for serious fungal infections, such as candidemia, Candida-derived peritonitis, intra-abdominal abscesses, and esophageal candidiasis. As a non-competitive inhibitor of 1,3-b-D-glucan synthase, which is responsible for the formation of glucan polymers, anidulafungin interferes with the cell wall synthesis of most pathogenic fungi. This mode of action is characteristic of the echinocandin class of antifungals. While the first member of this class, cilofungin, was withdrawn due to toxicity associated with the formulation vehicle, anidulafungin follows the successful introduction of caspofungin and micafungin. Compared to the other echinocandins, anidulafungin appears to be more potent (MIC90 ofr0.25 mg/mL for C.albicans, 0.5 mg/mL for C.glabrata, 1 mg/mL for C. krusel and C.tropicalis, 2mg/mL for C.lusitaniae, and 2 mg/mL for Aspergillus spp) and is devoid of significant drug interactions since it is neither an inhibitor nor substrate of the cytochrome P450 isoenzymes. The emergence of the echinocandins circumvents the concern regarding the rising resistance to the azole and amphotericin B antifungals; no cross-resistance is expected because the echinocandins work at the cell wall rather than the cell membrane.
Originator	Eli Lilly (US)
Uses	Anidulafungin is a semi-synthetic cyclic lipopeptide belonging to the echinocandin class that was reported in 1995 and commercially developed by Eli Lilly. Anidulafungin inhibits the synthesis of β-(1,3)-D-glucan, an essential component of the cell wall of susceptible fungi and is extensively referenced in the literature with over 400 citations.
Uses	nucleoside reverse transcriptase inhibitor (NRTI) for HIV treatment in adults

View All

Visit Store

You Might Also Like

Related Searches

Contact Supplier

Confirm to collect the product to my collection?

OK Cancel

About|Contact|Cas|Product Name|Molecular|Country|Encyclopedia

Message|New Cas|MSDS|Service|Advertisement|CAS DataBase|Article Data|Manufacturers | Chemical Catalog

©2008 LookChem.com,License: ICP

NO.:Zhejiang16009103

complaints:service@lookchem.com Desktop View